Product details
Catalog number BNC741222-100
Price for BNC741222-100
Size / count 1x 100 µL
UACA (Uveal Autoantigen with Coiled-coil domains and Ankyrin repeats) is a 1,416 amino acid nuclear membrane protein. It was originally identified as an autoantigen in patients with panuveitis, a characteristic of Vogt-Koyanagi-Harada disease, and in patients with Graves' disease. UACA was also later identified as Nucling, an mRNA differentially expressed in F9 embryonal carcinoma cells during cardiac muscle differentiation. UACA appears to function as a pro-apoptotic protein that recruits the apaf-1-pro-caspase-9 complex for the induction of apoptosis to mediate the cell-death pathway.Primary antibodies are available purified, or with a selection of fluorescent CF® Dyes and other labels. CF® Dyes offer exceptional brightness and photostability. Note: Conjugates of blue fluorescent dyes like CF®405S and CF®405M are not recommended for detecting low abundance targets, because blue dyes have lower fluorescence and can give higher non-specific background than other dye colors.
The catalog number for UACA / Nucling (UACA/1222), CF740 conjugate, 0.1mg/mL is BNC741222-100.
UACA / Nucling (UACA/1222), CF740 conjugate, 0.1mg/mL is available in the following size(s): 1x 100 µL.
UACA / Nucling (UACA/1222), CF740 conjugate, 0.1mg/mL is currently made to order / not held in immediate stock. Contact us for lead time.
UACA / Nucling (UACA/1222), CF740 conjugate, 0.1mg/mL is manufactured by Biotium.
Estimated delivery time for UACA / Nucling (UACA/1222), CF740 conjugate, 0.1mg/mL is approximately 15 business day(s), depending on your location.
The safety data sheet for UACA / Nucling (UACA/1222), CF740 conjugate, 0.1mg/mL is available here: https://cdn.gentaur.com/products/37/68dd02a0061270361e103d45/msds/bnc741222-100.pdf.
UACA (Uveal Autoantigen with Coiled-coil domains and Ankyrin repeats) is a 1,416 amino acid nuclear membrane protein. It was originally identified as an autoantigen in patients with panuveitis, a characteristic of Vogt-Koyanagi-Harada disease, and in patients with Graves' disease. UACA was also late
Yes, custom antibody development and private-label production services are available. Contact our sales team to discuss your target, timeline, and quantity requirements.
Immunogen or antigen details used to raise this antibody are listed on the product datasheet under immunogen information.
A recommended positive control, where one is specified by the manufacturer, is listed on the datasheet or in the assay protocol.